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Objective: Genetic associations imply a role for CD8+ T cells and the IL-23/IL-17 
axis in psoriatic arthritis (PsA) and other spondyloarthritides (SpA). IL-17A+CD8+ 
(Tc17) T cells are enriched in the synovial fluid of patients with PsA and IL-17A 
blockade is clinically efficacious in PsA/SpA. Our aim was to determine the 
immunophenotype, molecular profile and function of synovial Tc17 cells in order to 
elucidate their role in PsA/SpA pathogenesis. 
Methods: Peripheral blood (PB) and synovial fluid (SF) mononuclear cells were 
isolated from patients with PsA/SpA. Cells were phenotypically, transcriptionally and 
functionally analysed by flow cytometry (n=6-18), TCRβ sequencing (n=3), RNA-seq 
(n=3), RT-qPCR (n=4) and Luminex/ELISA (n=4-16).  
Results: IL-17A+CD8+TCRαβ+ T cells were increased in the SF vs. PB of patients 
with established PsA (p<0.0001) or other SpA (p=0.0009). TCRβ sequencing 
showed these cells are polyclonal in PsA (median clonality = 0.08), whilst RNA-seq 
and deep-immunophenotyping revealed that PsA synovial Tc17 cells have hallmarks 
of Th17 (RORC/IL23R/CCR6/CD161) and Tc1 cells (granzyme A/B). Synovial Tc17 
cells showed a strong tissue-resident memory T cell signature and secreted a range 
of pro-inflammatory cytokines. We identified CXCR6 as a marker for synovial Tc17 
cells, and increased levels of CXCR6 ligand CXCL16 levels in PsA SF (p=0.0005), 
which may contribute to their retention in the joint.  
Conclusion: Our results identify synovial Tc17 cells as a polyclonal subset of tissue-
resident memory T cells characterised by polyfunctional, pro-inflammatory mediator 
production and CXCR6 expression. The molecular signature and functional profiling 
of these cells may help explain how Tc17 cells can contribute to synovial 








Psoriatic arthritis (PsA) is part of an umbrella group of inflammatory diseases, 
termed spondyloarthritis (SpA), which share common patterns of joint inflammation 
(peripheral and axial), skin, gut and eye manifestations, genetic components, and 
the absence of diagnostic autoantibodies (seronegative). In addition to psoriatic 
arthritis (PsA), SpA includes ankylosing spondylitis/non-radiographic axial spondylitis 
(AS/NRAS), reactive arthritis (ReA), enteropathic arthritis (EA) and undifferentiated 
SpA, with a combined prevalence of 1-2% (1). 
 
It is increasingly recognised that the IL-23/IL-17 pathway plays a major role in 
PsA/SpA immunopathogenesis (2, 3). Therapies targeting IL-17A show clinical 
efficacy in patients with PsA and AS (4, 5), whilst several genetic loci implicated in 
the IL-17/IL-23 axis including IL12B (IL-12p40), IL23R and TRAF3IP2 (Act1) are 
associated with PsA and AS susceptibility (6, 7). To date, the majority of studies 
have focused on identifying IL-17A producing CD4+ T (Th17) cells or innate 
lymphoid type 3 (ILC3) cells in the inflamed joints of patients with PsA/SpA, yet the 
strong association of MHC class I and other CD8+ T cell/MHC class I related loci 
(RUNX3, ERAP1/2) suggests that CD8+ T cells play an important role in PsA/SpA 
(7-9). We previously demonstrated the enrichment of IL-17A-expressing CD8+ T 
(Tc17) cells in the synovial fluid of patients with PsA (10); Tc17 cells have also been 
reported in the synovial fluid of patients with juvenile idiopathic arthritis (11) and at 
the site of inflammation in other immune-mediated inflammatory diseases (reviewed 
in (2, 12)). Recent murine models and transcriptional analysis of healthy human 
spleen Tc17 cells have shed light onto the function of Tc17 cells (13, 14). However, 
functional and molecular analysis of human synovial Tc17 cells is essential to 
elucidate the role of synovial Tc17 cells in PsA/SpA pathogenesis. 
 
The enrichment of Tc17 in the inflamed joint raises the question as to whether these 
cells migrate into the joint or are persistently present. Recently, a novel subset of 
CD8+ effector T cells enriched in tissue compartments without significant presence 
in the blood has been described (15). These tissue resident memory (TRM) T cells 
are characterised by expression of CD69 and CD103, defined by a core 
transcriptional signature (16) and possess the potential to produce pro-inflammatory 
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cytokines including IL-17A, IL-22 and IFN-g, as well as granzymes and perforin 
(reviewed in (17, 18)). The presence of TRM cells in humans has been described in 
skin, lung, gut and brain tissue and a recent study reported the presence of CD8+ T 
cells with a tissue-resident memory phenotype in the synovial fluid of JIA patients 
(11). As such, TRM cells are hypothesised to contribute to the immunopathogenesis 
of human immune-mediated inflammatory disease. However, if and how Tc17 and 
TRM cells relate to each other is not well established.  
 
To enhance our understanding of the function and molecular biology of human IL-
17A+ CD8+ T cells, we performed extensive phenotypic, molecular and functional 
profiling of human Tc17 cells derived from the PsA synovial fluid. Using flow 
cytometry, TCR sequencing, Luminex and RNA-seq analysis, we demonstrate that 
PsA synovial IL-17A+ CD8+ T cells have a polyclonal TCR repertoire, a 
polyfunctional, pro-inflammatory cytokine profile, and many hallmarks of TRM cells. 
These features position Tc17 cells as relevant contributors to the initiation or 
perpetuation of chronic inflammation in PsA, and possibly other SpA or IL-17A/HLA 






MATERIALS AND METHODS 
Study subjects 
Peripheral blood and synovial fluid samples were obtained from patients with 
psoriatic arthritis or other peripheral SpA (ankylosing spondylitis/non-radiographic 
axial-SpA, reactive arthritis, enteropathic arthritis) attending the Rheumatology 
Department, Guy’s Hospital. Patients fulfilled the CASPAR or 2010 ACR/EULAR 
criteria (19, 20). Demographic and clinical characteristics of patients are shown in 
Supplementary Table 1. All subjects provided written informed consent. Ethical 
approval was obtained from Bromley Research Ethics Committee (06/Q0705/20) and 
Harrow Research Ethics Committee (17/LO/1940). 
 
Cell isolation 
Mononuclear cells (PBMC and SFMC) were isolated using LymphoprepTM (Axis-
Shield, Oslo, Norway) and washed in culture medium (RPMI 1640 supplemented 
with 10% FSC + 1% penicillin, streptomycin, L-glutamine). Cells were cryopreserved 
and stored in liquid nitrogen in culture medium supplemented with 50% FCS and 
10% dimethyl sulfoxide (all Thermo-Fisher, Waltham, MA, USA).  
 
Flow cytometry 
Thawed cells were rested for 1 hr at 37°C, 5% CO2. For intracellular staining 
samples were stimulated with phorbol myristate acetate (PMA, 50 ng/ml) and 
ionomycin (750 ng/ml, both Sigma-Aldrich, St Louis, MO, USA) in the presence of 
Golgistop (BD Biosciences, Franklin Lakes, NJ, USA) for 3 hours at 37°C, 5% CO2. 
Cells were stained with eFluor780 Viability Dye (eBioscience, San Diego, CA, USA) 
and surface staining was performed at 4°C. Cells were fixed with 2% PFA and 
permeabilised using 0.5% Saponin (Sigma-Aldrich). Antibodies are described in 
Table S2. Samples were acquired using an LSR-Fortessa (BD Biosciences). Data 
were analysed using FlowJo (v10, Tree Star, Ashland, OR). 
 
TCRβ sequencing  
Extracted DNA (Qiagen, Venlo, Netherlands) underwent bias-controlled amplification 
of VDJ rearrangements followed by high throughput sequencing (ImmunoSEQ, 
Adaptive Biotech, Seattle, WA, USA). Data from productive reads (sequence level) 
6 
 
were analysed using the ImmunoSEQ analysis platform (Adaptive Biotech). Clonality 
was defined as 1-Pielou’s Evenness and ranged from 0 (indicating a highly 
polyclonal repertoire) to 1 (indicating a monoclonal repertoire). Overlap was 
determined using Morisita’s index ranging from 0 (indicating no similarity between 
two populations) to 1 (indicating complete similarity between two populations). 
 
Cell sorting  
For TRM T cell sorting, SFMC were stained with eFluor780 and CD3, CD4, CD8, 
CD14, CD69 and CD103 antibodies (Supplementary Table 2). Post sort, CD8+ TRM 
subsets were stimulated, fixed and permeabilised before intracellular cytokine 
staining for IL-17A and IFN-g. For sorting of cytokine producing cells, magnetically 
isolated (Miltenyi Biotec, Bergisch Gladbach, Germany) CD3+ T cells were 
stimulated for 1.5 hours at 37oC with PMA (50 ng/ml) and ionomycin (750 ng/ml) 
before staining using an IL-17A and, where indicated, IFN-γ cytokine secretion assay 
(Miltenyi). To identify cytokine-producing T cell subsets, cells were counter stained 
with eFluor780 and anti-CD3, CD8, CD14 and CD4 antibodies. Cells were sorted 
using a BD FACS Aria and acquired using an LSR-Fortessa (BD Biosciences).  
 
RNA sequencing and RT-qPCR  
Libraries were prepared by GENEWIZ LTD (South Plainfield, NJ, USA) and 
sequenced on the HiSEQ2500 platform (Illumina, San Diego, CA, USA) at a depth of 
28-40M reads. Low quality (phred score <20) bases and adapters were trimmed 
using TrimGalore! and reads aligned (hg38) using RNA STAR. Paired reads were 
quantified using FeatureCounts. PCA analysis and statistical comparison of gene 
expression was performed using DESeq2.  
 
For RT-qPCR, total RNA was extracted from sorted cell subsets (Qiagen). cDNA was 
generated using the high capacity cDNA reverse transcription kit (Thermo-Fisher). 
RT-PCR was performed using the SensiFAST SYBR kit (Bioline, Cincinnati, OH, 
USA) and primers from Integrated DNA Technologies (Coralville, IA, USA) listed in 





Luminex assay and CXCL16 ELISA 
Supernatants were obtained from sorted T cell subsets cultured for 24-hours in 
culture media. A custom magnetic Luminex (Bio-Techne, Minneapolis, MN, United 
States) was analysed on the Luminex FlexMap 3D platform (Austin, TX, United 
States). Serum and synovial fluid were analysed using a CXCL16 ELISA (Bio-
Techne).   
 
Graphics and statistical analysis 
Statistical analysis and graphical illustration was performed using either PRISM (v7, 
GraphPad, San Diego, CA, US), or ggplot2 using R version 3.5.2. Results are 
expressed as the median + interquartile range (IQR). Wilcoxon's matched pairs 
























Tc17 cells are polyclonal TCRαβ+ memory cells enriched in PsA/SpA joints 
 
To determine whether synovial Tc17 are enriched only in PsA, or also in other SpA, 
we stimulated paired PBMC and SFMC from patients with PsA, other SpA types or 
RA ex vivo with PMA/ionomycin and assessed the frequency of IL-17A+ CD8+ T 
cells by flow cytometry (Figure 1A, B; gating strategy in Supplementary Figure S1). 
Low frequencies of Tc17 cells were detected in PBMC from PsA, other SpA and RA 
patients (median 0.1%), with no significant differences observed between these 
groups. The frequencies of Tc17 cells were significantly increased in SFMC 
compared to PBMC in patients with PsA (p<0.0001) and other SpA types 
(p=0.0009), but not RA (p=0.16). The frequencies of Th17 cells were similar between 
the three disease groups (Supplementary Figure S1B). 
 
Synovial Tc17 cells were predominantly comprised of TCRab+ cells, with small 
proportions of MAIT (Va7.2+), gd and NKT cells (Figure 1C, D). Over 98% of synovial 
Tc17 cells exhibited a memory phenotype (CD45RA-CD27+/-; Figure 1E, F), whilst a 
considerable proportion of Tc17 cells expressed the immunoinhibitory receptor 
programmed cell death protein 1 (PD1; median 65%) and activation marker HLA-DR 
(51%), suggesting these cells previously experienced antigen stimulation (Figure 1G, 
H).  
 
The presence of clonally restricted memory CD8+ T cells with features of antigen-
specific expansion has been described in the synovial fluid, synovial tissue and skin 
of patients with PsA (21-23). To investigate whether in PsA, synovial Tc17 cells are 
also clonally restricted, bulk memory (CD45RA-CD27+/- and CD45RA+CD27-), IL-
17A+IFN-γ+/- (Tc17) and IL-17A-IFN-γ+ (Tc1) memory CD8+ T cells were sorted 
from the SF of PsA patients (gating strategy in Supplementary Figure S2). TCRb 
sequencing revealed that synovial Tc17 cells display a diverse TCR repertoire 
(Figure 2A) with a low clonality score (Pielou evenness), which was similar to 
synovial Tc1 and bulk memory CD8+ T cells (Figure 2A, B). For two patients, a 
substantial proportion of the clones found in synovial Tc17 cells were also present in 
the synovial Tc1 population, resulting in a Morisita overlap index >0.9 (Figure 2C, D). 
9 
 
The third patient had a lower number of productive templates, which may have 
resulted in a low Morisita score.  
 
Molecular analysis of synovial Tc17 cells reveals commonalities in 
transcriptional profile with Th17 and Tc1 cells  
 
Recent transcriptional analysis of healthy human spleen Tc17 cells revealed a 
distinct molecular profile compared to IL-17- CD8+ T cells or Th17 cells (14). To 
determine the molecular profile of Tc17 cells from the inflamed PsA joint, we sorted 
highly pure Tc17, Tc1 and Th17 cells from the SFMC of patients with PsA for RNA 
sequencing (gating strategy Supplementary Figure S3). Accurate sorting was 
confirmed by the normalised gene counts of IL17A and IFNG for each of the 
populations (Supplementary Figure S3B). Principal component analysis showed a 
degree of gene expression heterogeneity between synovial Tc17 cells from different 
patients. In 2/3 patients, the synovial Tc17 cells clustered separately from the Th17 
cells but close to the Tc1 cells (Figure 3A, B), suggesting a proportion of the 
transcriptional profile between synovial Tc17 and Tc1 cells is shared. In total, 80 
genes were differentially expressed between the synovial Tc17 and Tc1 subsets 
(£1%FDR, fold change >2; MA plots shown in Figure 3C with the ten most up- or 
down regulated genes indicated). Several genes relating to a type 17 response 
(IL17A, IL17F, RORC, IL23R, CCR6 and KLRB1) were elevated compared to 
synovial Tc1 cells (Figure 3C, E). When synovial Tc17 cells were compared to 
synovial Th17 cells, 145 genes were found to be differentially expressed (Figure 3D). 
Upregulated genes in synovial Tc17 cells compared to Th17 cells included CD8A 
and CD8B, confirming our gating strategy, plus genes associated with cytolytic 
activity (GRZA, GRZB and PRF1) (Figure 3D, F). Expression levels of TCF7 
(encoding TCF-1), recently identified as a transcriptional regulator of mouse Tc17 
cells through repression of MAF and RORgt (14) was low in synovial Tc17 cells 
(Supplementary Figure S3C).  
 
We confirmed the transcriptional data for the type 17 markers chemokine receptor 6 
(CCR6) and Killer cell lectin-like receptor subfamily B member 1 (CD161) at the 
protein level by flow cytometry. A high frequency of synovial Tc17 cells co-expressed 
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CCR6 or CD161, at levels comparable to synovial Th17 cells. In contrast, only 
limited proportions of synovial IL-17A- CD8+ or IFN-g+ CD8+ T cells expressed 
these molecules (Figure 4A, B). viSNE analysis showed that CCR6 and CD161 were 
co-expressed by Tc17 cells (Figure 4C, representative of n=7). Notably, this analysis 
also revealed that CCR6 and CD161 expression is not restricted to the IL-17A+ 
population, i.e. these markers do not exclusively define IL-17A expression in synovial 
CD8+ T cells. RT-qPCR analysis further confirmed that transcript levels of retinoic 
acid receptor-related orphan receptor C (RORC) and interleukin 23 receptor (IL23R) 
in the synovial Tc17 population were comparable to Th17 cells, and higher than in 
IL-17A- CD8+ T cells (which contains IFN-g+ CD8+ T cells) (Figure 4D).  
 
Frequencies of granzyme A, granzyme B, CD107a and perforin expressing cells 
within Tc17 cells were variable but enhanced compared to synovial Th17 cells, whilst 
they were comparable to those within synovial Tc1 cells (Figure 4E, F). It should be 
noted however that limited expression of perforin and LAMP1/CD107a was observed 
in synovial Tc17 cells, suggesting these cells may not have full cytotoxic capability.  
 
Tc17 cells have hallmarks of tissue-resident memory T cells 
 
The observation that Tc17 cells with a memory phenotype are enriched in the PsA 
joint but not the blood prompted us to investigate whether synovial Tc17 cells from 
the inflamed joint expressed markers of tissue residency. Our molecular profiling 
revealed that genes reported to be transcriptional hallmarks of tissue resident 
memory (TRM) cells (e.g. ITGAE (encoding CD103), ZNF683 (encoding HOBIT), 
CRTAM and low levels of S1PR1) (16) were differentially expressed between 
synovial Tc17 and Th17 cells (Figure 5A). We confirmed the expression of the TRM 
cell marker CD103 (aE integrin) on a high proportion of joint-derived Tc17 cells by 
flow cytometry (Figure 5B, C). CD69, which is also commonly used as TRM marker, is 
upregulated upon PMA/ionomycin stimulation and was therefore not determined. 
Since Tc17 cells have been identified in the gut and the skin (24-27), sites that can 
also be affected in PsA/SpA, we assessed markers for the gut-related molecule 
integrin β7 (which is normally co-expressed with aE integrin) and the skin-related 
adhesion/homing molecules, cutaneous lymphocyte antigen (CLA) and CD49a (very 
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late antigen; VLA1). Considerable proportions of synovial Tc17 cells co-expressed 
integrin β7, CD49a/VLA-1 and to a lesser extent CLA (Figure 5B, C).  
 
Based on these findings, we examined the presence of TRM cells using the markers 
CD69 and/or CD103 in unstimulated SFMC from PsA patients (Figure 5D, E). Within 
the CD8+ T cell population, on average 11% of cells were CD69+CD103+ (range 2-
16%), 26% of cells were CD69+CD103- (range 3.2-54%), and 6% of cells were 
CD69-CD103+ (range 1.29-16%). In the CD4+ compartment, 26% of the cells were 
CD69+CD103- whilst CD103 expression was negligible (expressed by <1% of CD4+ 
T cells). These data indicate that CD103+ TRM cells in the inflamed PsA joint typically 
are CD8+ T cells. 
 
To directly demonstrate that CD8+ TRM cells contain IL-17A producing cells, we 
sorted synovial CD8+ T cells from PsA patients into highly pure CD69+CD103+, 
CD69+CD103-, CD69-CD103+ and CD69-CD103- subsets (gating strategy shown in 
Supplementary Figure S4). The sorted cells were then stimulated ex vivo and 
stained for IL-17A and IFN-g (Figure 5F, G). After normalising for total cytokine 
expression, we identified that the CD69+CD103+ CD8+ T cell population contained 
the highest frequency of IL-17A+ cells, followed by CD69+ or CD103+ single 
expressing cells, whilst CD69-CD103- CD8+ T cells contained minimal IL-17A+ cells 
(Figure 5H). In contrast, frequencies of IFN-γ+ cells were distributed more equally 
amongst the 4 sorted cell subsets. We also found a significant correlation between 
the presence of IL-17A+ CD8+ T cells and CD69+CD103+ TRM cells in the synovial 
fluid, further supporting a relationship between these two cell populations 
(Supplementary Figure S5). Together, these data indicate that synovial TRM cells are 
enriched for IL-17A expression and that Tc17 cells form part of the tissue-resident 
memory T cell pool in the inflamed synovial joints in PsA.  
 
Synovial Tc17 cells are polyfunctional inflammatory cells characterised by 
high expression of CXCR6 
 
As a final step we sought to determine the functional potential of synovial Tc17 cells. 
For this, we assessed the co-expression and secretion of pro- and anti-inflammatory 
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cytokines by flow cytometry and Luminex. A substantial proportion of synovial Tc17 
cells co-expressed pro-inflammatory IFN-g, TNF-a and GM-CSF, whilst IL-21 was 
co-expressed by less than 20% of Tc17 cells. IL-22 and anti-inflammatory IL-10 were 
found to be either absent or expressed by only a small proportion of Tc17 cells 
(Figure 6A, B). IL-17F was found to be co-expressed by only a small proportion of 
Tc17 cells (Supplementary Figure S6B). The cytokine co-expression profile of 
synovial Tc17 cells closely resembled the cytokine profile of synovial Th17 cells 
(Figure 6B, right panel), whilst this profile was not shared by synovial IL-17A- CD8+ 
or IFN-γ+ CD8+ T cell subsets (Supplementary Figure S6A). Overall, synovial Tc17 
cells displayed a polyfunctional cytokine profile with a sizable proportion of cells 
(median 36%), expressing IL-17A, IFN-g and TNF-a concomitantly (Figure 6C). This 
concomitant cytokine production was also observed in the Luminex analysis: sorted 
IL-17A+ CD8+ T cells from the synovial fluid of patients with PsA (gating strategy in 
Supplementary Figure S7) produced IL-17A, IFN-g, TNF-a, GM-CSF and IL-22, with 
low levels of IL-21 and IL-10 during 24hr culture (Figure 6D). 
 
Finally, we investigated whether Tc17 cells from the inflamed PsA joint express a 
unique set of markers. For this, we compared the transcriptional profile of synovial 
Tc17 cells to the profiles of both synovial Tc1 and Th17 cells, to determine which 
markers are uniquely upregulated in synovial Tc17 cells. Bioinformatic analysis 
revealed that 15 genes were upregulated in both comparisons, suggesting synovial 
Tc17 cells have a small unique transcriptional profile in comparison to synovial Tc1 
and Th17 cells (Figure 6E). Of these 15 genes, 6 were genes were found to be 
consistently upregulated in all three patients: CXCR6, NCR3, CHN1, LINC02195, 
LINC01871 and GOLIM4. Since CXCR6 is part of the TRM gene signature (16), we 
validated CXCR6 at the protein level and found that PsA synovial Tc17 cells indeed 
expressed CXCR6 at the highest level and contained the highest proportion of 
CXCR6-expressing cells as compared to their synovial Tc1 and Th17 counterparts 
(Figure 6F).  In addition, levels of CXCL16, the ligand for CXCR6, were significantly 







We previously described an enrichment of IL-17A+ CD4- (the majority of which were 
CD8+) T cells in the synovial fluid of patients with PsA compared to the peripheral 
blood (10). Here we show frequencies of IL-17A+ CD8+ T cells are also increased in 
the synovial fluid of patients with other types of SpA, and confirm these cells are not 
increased in RA (10). These findings add to the growing evidence that CD8+ T cells 
and the IL-17/IL-23 axis are relevant to the immunopathogenesis of PsA/SpA (2). We 
demonstrate that the vast majority of PsA synovial Tc17 cells are memory cells, 
indicated by a CD45RA-PD1+HLA-DR+ profile, as well as ab TCR bearing, 
suggesting these cells are MHC class I restricted and antigen-experienced. Previous 
studies demonstrated oligoclonal expansion of joint-derived bulk T cells in PsA (21-
23). Our TCRβ sequencing of synovial Tc17 cells, although limited in sample size, 
showed that although some T cell clones occupied >5% of the total TCR repertoire, 
the majority of Tc17 cells, as well as of the bulk memory CD8+ T cells and Tc1 cells, 
had a polyclonal TCR repertoire. One reason for the differences observed between 
the previous studies and our own could be patient disease activity. A study 
investigating the clonality of psoriatic skin-derived CD8+ T cells reported that the 
TCR repertoire is polyclonal in active disease, whilst in resolved disease only a few 
dominant clones persist (28). We obtained synovial fluid effusions from actively 
inflamed joints, which could explain the observed polyclonal repertoire. It would be of 
interest to investigate if a polyclonal repertoire is also observed in resolved PsA 
joints, however, this would require a synovial biopsy study design as non-inflamed 
joints rarely contain sufficient synovial fluid for aspiration.  
 
A notable observation in our analysis was the extensive sharing of T cell clones 
between the synovial Tc17 and Tc1 populations. Our RNAseq analysis also showed 
significant overlap in transcriptional profile between Tc17 and Tc1 cells. A possible 
explanation for these findings is that synovial Tc17 and Tc1 cells may have shared 
ancestry which raises the question of plasticity between these subsets. Adoptive 
transfer of in vitro generated Tc17 cells into recipient mice showed that Tc17 cells 
can switch to an IL-17A-negative Tc1 profile (29-31). A direct demonstration of this 
phenomenon came from an elegant IL-17A fate mapping study using reporter donor 
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IL-17CreRosa26eYFP (13). This study showed that Tc17 cells developed early after 
allogeneic stem cell transplantation in both lymphoid tissue and graft-versus-host-
disease target organs. However, their production of IL-17A was transient whilst IFN-
g production was largely maintained, a process defined by the surrounding cytokine 
milieu. A similar capacity to transition to IFN-g production and Th1 phenotype had 
previously been shown for mouse Th17 cells (32). These fate mapping data, 
together with our findings on shared TCR and transcriptional profiles and the 
observation that a high frequency of synovial Tc17 cells express IFN-g, could 
suggest that synovial Tc17 cells can transition to a Tc1-like cytokine profile, as was 
previously suggested for Th17 and Th1 cells in the JIA joint (33). If this is indeed the 
case, then one implication of this finding would be that the percentage of IL-17A+ 
CD8+ T cells detected by flow cytometry may underrepresent the contribution that 
Tc17 cells make or have made to the synovial T cell compartment.  
 
In addition to Tc17/Tc1 overlap, we observed a phenotypic and molecular overlap 
between Tc17 and Th17 cells in PsA, as evaluated by RNA-seq, RT-qPCR and flow 
cytometry. Two markers typically expressed by Th17 cells, CCR6 and CD161 (34-
36), are co-expressed by a large proportion of synovial Tc17 cells. Furthermore, 
expression of IL23R by synovial Tc17 cells indicates that IL-23 may be involved in 
generation or maintenance of these cells, whilst elevated RORC transcript 
expression suggests that RORgt may at least play a part in IL-17A regulation in these 
cells. These data indicate that Tc17 cells may be regulated by similar pathways as 
Th17 cells.   
 
The relatively limited sample sizes in the TCR and RNA-seq analysis could be 
considered a limitation of our study. However, given the challenges in obtaining 
sufficient numbers from small populations of immune cells, this number of samples 
(n=3) is not uncommon in studies on human tissue-derived cells. In further 
mitigation, many of our RNA-seq results were independently validated at the protein 
or RNA level. A further limitation of our work is that we did not have access to 
synovial tissue samples from patients with PsA. Nonetheless, the work presented 
here provides an important basis for future studies aimed at comparing the 
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phenotype and molecular profile of synovial fluid and synovial tissue-derived Tc17 
cells. 
 
A key novel finding from our work is that synovial Tc17 cells are part of the tissue-
resident memory T cell compartment and express molecules that prevent egress 
from the inflamed tissue into the blood. TRM cells are rapidly emerging as potential 
contributors to inflammation in several immune-mediated inflammatory diseases (17, 
37).  To our knowledge, the data presented here are the first description that Tc17 
cells form part of the synovial TRM pool and only the second description of TRM-like 
cells in the context of human immune-mediated arthritis (11). Our data also show 
that a high proportion of synovial Tc17 cells express markers typically associated 
with homing to the skin or gut. This could indicate that synovial Tc17 cells have 
tropism for these tissues as well as for the synovial compartment and indeed, the 
presence of Tc17 cells has been described in both the skin and the gut (24, 25, 27). 
An alternative explanation could be that synovial Tc17 cells expressing these 
markers have enhanced adherence to the surrounding joint tissue, as both CLA and 
CD49a ligands (E-selectin and Type IV collagen, respectively) are present in the 
synovial tissue (38, 39). Integrin β7, which is expressed by a large proportion of 
synovial Tc17 cells, can form a heterodimer with the TRM cell marker CD103 (αE 
integrin), which is expressed by Tc17 cells. The product, αEβ7 integrin, exclusively 
binds E-Cadherin, a structural protein expressed in the synovial joint and fluid of 
patients with inflammatory arthritis (39, 40). Interaction of synovial Tc17 cells with the 
surrounding tissue and extracellular matrix in the fluid combined with lack of 
response to exit cues (e.g. S1P1) could represent one way by which Tc17 cells are 
retained in the synovial joint and contribute to perpetuation or re-initiation of 
inflammation. Residence of synovial Tc17 cells in the inflamed tissue may be further 
enhanced by their high expression of CXCR6, a marker of TRM cells (16), in 
combination with the increased levels of CXCL16 in the PsA synovial joint. CXCL16 
has chemotactic and angiogenic properties and can be produced as a soluble 
mediator or as a transmembrane-bound chemokine by monocytes, macrophages 
and dendritic cells. Evidence of increased CXCL16 and CXCR6 expression at the 
site of inflammation was reported previously in the context of RA and psoriasis, and 
CXCL16 was shown to enhance recruitment of inflamed tissue-derived CXCR6-
expressing T cells (41-43). Furthermore, CXCL16 blockade or CXCR6 deficiency led 
16 
 
to reduced arthritis scores and lower IFN-g/IL-17 production in an experimental 
model of arthritis (42, 44). Together, these data suggest that the increased CXCR6 
expression on synovial Tc17 cells may contribute to their recruitment and 
persistence in the inflamed PsA joint.  
 
Functionally, our data indicate that synovial Tc17 cells are polyfunctional and actively 
secrete several pro-inflammatory cytokines (IFN-γ, TNF-α, GM-CSF, IL-21 and IL-
22) in parallel to IL-17A, but little IL-10 or IL-17F. IFN-γ, TNF-α and GM-CSF have all 
been shown to act synergistically with IL-17A to promote inflammation. In a recent 
study by Wade et al. polyfunctional CD8+ T cells were also found to be enriched in 
the PsA synovium, although enrichment was not observed for single cytokine 
producing T cells, including IL-17A+ CD8+ T cells (45). Concordant with their pro-
inflammatory cytokine production, Tc17 cells co-expressed cytolytic molecules 
granzyme A and granzyme B at comparable levels to synovial Tc1 cells. However, 
Tc17 cells lacked significant expression of other cytolytic machinery (perforin and 
LAMP1). Most studies to date in both mice and humans report that Tc17 cells lack 
cytolytic function (29, 31, 46, 47), although some evidence for cytotoxic function has 
been reported (24, 48). An interesting alternative interpretation of our data is that the 
secretion of granzymes is not cytolytic but leads to extracellular matrix degradation 
or promotion of inflammation (49, 50). Collectively, these data show that Tc17 cells 
are armed with an array of pro-inflammatory mediators, which could act directly on 
surrounding cells to promote inflammation in the synovial joint.  
 
In summary, our findings reveal that synovial Tc17 cells from the PsA joint bear 
hallmarks of tissue resident memory T cells, and express high levels of CXCR6, 
which may enhance retention of these cells in the inflamed joint. Our analysis of the 
transcriptional profile and TCR repertoire of these cells highlights several 
commonalities between Tc17 and Tc1 cells in the PsA joint. Combined with the 
observed polyfunctional pro-inflammatory mediator production, we hypothesise that 
Tc17 cells exert heterogenous effector responses which contribute to initiation and 
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Figure 1. IL-17A+ TCRαβ+ CD8+ T cells are enriched in the synovial fluid of 
patients with SpA. A) Representative staining and B) cumulative data depicting 
frequencies of IL-17A+ cells within CD3+ CD8+ T cells in paired PBMC and SFMC 
from patients with PsA (left, n=18), other peripheral SpA (centre, n=14) or RA (right, 
n=6) after 3 hours stimulation in the presence of PMA, ionomycin and Golgistop. 
Data were analysed using Wilcoxon's matched pairs signed rank test. C) 
Representative staining and D) cumulative data (median + IQR) showing the 
frequency of αβ TCR (n=8), γδ TCR (n=9), CD56 (n=7) and Vα7.2 (n=6) expressing 
IL-17A+ CD8+ T cells from PsA SF (stimulated as before). E) Representative 
staining and F) frequencies of CD45RA and/or CD27 expressing cells (median + 
IQR) within IL-17A+ CD8+ T cells from the SFMC of patients with PsA (n=6) 
(stimulated as before). G) Representative staining and H) cumulative data (median + 
IQR) showing the frequencies of PD-1 and HLA-DR expressing IL-17A+ CD8+ T 
cells from PsA patients (n=6).  
 
Figure 2. Synovial Tc17 cells have a diverse TCR repertoire A) Representative 
pie charts showing the frequency of all TCRβ sequences in bulk CD8+ memory, IL-
17A+ CD8+ and IL-17A- IFN-γ+ CD8+ T cells. B) Clonality score (defined as 1-
Pielou’s evenness) of bulk CD8+ memory, IL-17A+ CD8+ and IL-17A- IFN-γ+ CD8+ 
T cells from PsA synovial fluid samples (n=3). C) Individual dot plots and D) clonal 
overlap defined as Morisita’s index between IL-17A+ CD8+ and IL-17A- IFN-γ+ 
CD8+ T cells. 
   
Figure 3. Transcriptional profile of synovial Tc17 cells compared to Tc1 and 
Th17 cells. A, B) Principal component analysis of the transcriptome of IL-17A+ 
CD8+, IFN-γ+ CD8+ and IL-17A+ CD4+ T cells from the synovial fluid of PsA 
patients (n=3), colour-indicated by cell type (A) or patient (B). (C, D) MA plots and (E, 
F) selected gene expression profiles shown as average gene expression values 
(FPKM) of synovial IL-17A+ CD8+ compared to IFN-γ+ CD8+ T cells or CD4+ IL-
17A+ T cells (n=3). In C, D: grey points = adjusted p value>0.01, blue points = 





Figure 4. Synovial Tc17 cells have functional hallmarks of Th17 and Tc1 cells. 
A) Representative staining and B) cumulative data showing the frequency of IL-17A+ 
CD8+, IL-17A+ CD4+, IL-17A- CD8+ and IFN-γ+ CD8+ T cells from SFMC of 
PsA/SpA (PsA = colour symbols; other SpA = white symbols) expressing CCR6 
(n=7-9) and CD161 (n=7-9) (median + IQR). C) Representative ViSNE plot showing 
concomitant expression of IL-17A, CCR6 and CD161 within CD8+ T cells from the 
SFMC of PsA patients (representative of n=7). D) Gene expression levels of RORC 
and IL23R normalised to the average values for 18S and UBC in sorted IL-17A+ 
CD8+, IL-17A- CD8+ and IL-17A+ CD4+ T cells from PsA SFMC (n=4). E) 
Representative staining and F) cumulative data (median + IQR) showing the 
frequencies of granzyme A (n=4), granzyme B (n=9), LAMP1 (n=6) and perforin 
(n=6) expressing cells within IL-17A+ CD8+, IFN-γ+ CD8+ or IL-17A+ CD4+ T-cells 
from SFMC of PsA patients. Analysed using Friedman multiple comparisons test 
 
Figure 5. Synovial Tc17 form part of the synovial tissue-resident T cell 
compartment. A) Selected TRM-associated gene expression profiles of sorted 
synovial IL-17A+ CD8+ T cells compared to CD4+ IL-17A+ T cells (n=3). B) 
Representative staining and C) cumulative data (median + IQR) showing the 
frequencies of IL-17A+ CD8+ T cells from SFMC of patients with PsA expressing 
CD103/αE integrin (n=12), integrin β7 (n=7), CD49a/VLA1 (n=9) or CLA (n=12), after 
3 hours stimulation with PMA, ionomycin and Golgistop. D) Representative staining 
and E) frequencies of CD69+CD103+, CD69+CD103- and CD69-CD103+ TRM cells 
(median + IQR) within synovial CD3+CD8+ (n=12) and CD3+CD4+ T cells (n=12). F-
H) Cells from the synovial fluid of patients with PsA (n=3) were sorted into 
CD69+CD103+, CD69+CD103-, CD69-CD103+ and CD69-CD103- CD8+ T cells. 
Sorted subsets were stimulated with PMA and ionomycin in the presence of 
Golgistop for 3 hours. F, G) Representative staining showing IL-17A (F) and IFN-g 
(G) expression within the 4 sorted subsets. H) Proportion of IL-17A+ (left panel, n=3) 
or IFN-γ+ (right panel, n=2) cells in each TRM subset, as a fraction of total IL-17A or 





Figure 6. Synovial Tc17 cells are polyfunctional pro-inflammatory cells 
characterised by high expression of CXCR6 A) Representative and B) cumulative 
data (median+IQR) showing IFN-g (n=12), TNF-a (n=12), GM-CSF (n=9), IL-21 (n=6), 
IL-22 (n=6) and IL-10 (n=8) co-expressing cells within IL-17A+ CD8+ (left panel) and 
IL-17A+ CD4+ (right panel) T cells from PsA (closed symbols) or other SpA (open 
symbols) SFMC. (C) Proportion of IL-17A+ CD8+ T cells expressing IL-17A alone, IL-
17A plus TNF-α or IFN-γ, or IL-17A plus TNF-α and IFN-γ (median+IQR, n=7). D) IL-
17A, IFN-g, TNF-a, GM-CSF, IL-21, IL-22 and IL-10 secretion by sorted synovial IL-
17A+ CD8+ T cells (n=4) E) Venn diagram showing number of significantly 
upregulated genes (p<0.01) in IL-17A+ CD8+ T cells vs. (left) IFN-γ+ CD8+ or (right) 
IL-17A+ CD4+ T cells; heatmap indicates consistently upregulated genes in all 
patients. F) Representative dot plots/histograms and cumulative data (n=6) showing 
the percentage of CXCR6+ cells (left panels), and CXCR6 expression levels (right 
panels) in PsA synovial IL-17A+ CD8+ T cells, IFN-γ+ CD8+ T cells and IL-17A+ CD4+ 
T cells (Friedman multiple comparisons test). G) CXCL16 levels in paired PsA serum 
and synovial fluid samples (n=12) as measured by ELISA (Wilcoxon's matched pairs 
signed rank test). 
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